XBiotech Inc. (NASDAQ: XBIT) is a Healthcare company (Biotechnology) with a market capitalization of $54M. The Maz Rating grades it against the other companies in its sector.
XBiotech Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.78, XBiotech Inc. trades at 0.4x book value, with an EV/EBITDA of 1.3. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -33.0%, return on invested capital of -37.7% and a free cash flow yield of -75.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 39.51. Over the past 52 weeks the share price ranged from $1.78 to $2.73, with a beta of 0.74.
XBiotech Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, XBiotech Inc. (XBIT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 162.7% / 30% · Interest income / Revenue 83100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 162.7% / 33% · Receivables / Mkt Cap (36m) 0.41% / 49% · Interest income / Revenue 83100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 162.7% / 33.33% · Receivables / Mkt Cap (24m) 0.41% / 33.33% · Interest income / Revenue 83100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 82.5% / 33.33% · Receivables / Avg Assets (4Q) 0.22% / 33.33% · Interest income / Revenue 83100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 81.7% / 33.33% · (Cash+Recv) / Total Assets 81.9% / 33.33% · Interest income / Revenue 83100000.0% / 5% | Fail |
No. As of September 2026, XBiotech Inc. (XBIT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. XBiotech Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 83100000.0% of each dividend: XBiotech Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.